Interventional Hardware, EU as a Launchpad, EU’s Hidden Moat
A few days ago GE Healthcare launched a new ceiling-mounted intervention suit called Allia Celeo. What’s interesting about it is that it’s already CE-marked, while FDA approval is still pending.
A little research on the internet confirmed this was not the exception.
Major EU-Developed MedTech Launches (2021–2026)
|
Device / Platform |
Developer & EU R&D Hub |
Clinical Breakthrough |
European Launch vs. U.S. Timeline |
|
NAEOTOM Alpha (and Alpha Class) |
Siemens Healthineers (Forchheim, Germany) |
World’s first commercial photon-counting CT scanner, directly converting X-ray photons into electrical signals for ultra-high resolution at lower radiation doses. |
Clinical prototype installations and CE-mark launch began in Germany/Europe in 2021 (followed by the expanded Alpha.Peak/Pro/Prime class in late 2024), ahead of full U.S. FDA clearance for the new class in March 2025. |
|
MAGNETOM Free.Max & Free.Star |
Siemens Healthineers (Erlangen, Germany) |
Low-field (0.55T), virtually helium-free MRI platform using AI image reconstruction (Deep Resolve) to bring MRI to clinics without specialized cooling infrastructure. |
Developed with University Hospital Erlangen; first clinical routine installations launched in Erlangen, Germany (2021) before global expansion. |
|
Allia Moveo & Allia Celeo |
GE HealthCare (Buc, France) |
Next-generation mobile (Moveo) and ceiling-mounted (Celeo) AI-guided interventional C-arm systems with cable-free designs and real-time dose optimization. |
Allia Moveo completed its first global installation at Hôpital Marie-Lannelongue in France (February 2026); Allia Celeo launched with a CE mark in November 2026 while U.S. FDA 510(k) remains pending. |
|
Azurion Image-Guided Therapy (Next-Gen Neuro/Biplane) |
Philips (Best, Netherlands) |
Advanced biplane interventional suite integrating 3D brain perfusion imaging (SmartCT) and automated stroke workflow directly in the angio room. |
Engineered and clinically validated in the Netherlands and European stroke centers prior to North American rollout. |
|
Hugo RAS (Robotic-Assisted Surgery) |
Medtronic (Surgical robotics R&D in Germany/Ireland/U.S.) |
Modular, open-console multi-quadrant surgical robot competing with Intuitive's da Vinci system. |
Secured EU CE mark in October 2021 and performed its first European commercial surgeries in Belgium in February 2022, years before U.S. FDA clearance (remained investigational in the U.S. through 2025). |
|
Symphony & MyoVista / Next-Gen Pulsed Field Ablation (PFA) Systems |
Boston Scientific (FARAPULSE) / Medtronic (PulseSelect) / Abbott (European electrophysiology centers) |
Non-thermal Pulsed Field Ablation (PFA) catheters using high-voltage electrical pulses to treat atrial fibrillation without damaging surrounding tissue. |
Core clinical trials and initial commercial rollouts (CE mark in 2021–2023) occurred across Germany, France, and the Czech Republic 1 to 3 years before U.S. FDA approval (2024). |
|
Symplicity Spyral (Renal Denervation) |
Medtronic (Galway, Ireland & European clinical hubs) |
Minimally invasive catheter delivering radiofrequency energy to renal nerves to treat uncontrolled hypertension. |
Widely available and reimbursed across Europe (including Germany) for years prior to receiving U.S. FDA approval in late 2023. |
Regulatory approval tends to be easier and faster where the product was build and clinically validated. In this case, major med tech companies have R&D bases in Europe, which means they often launch EU-first.
This is good for any clinical product but it becomes especially powerful with interventional ones, which in addition to generating a ton of proprietary data, is what define the patient outcome.
Similar to how the iPhone transformed the mobile market, enabling an entirely new mobile app market, AI is transforming the medtech market, enabling an entirely new medical app market. Hardware enables data, data enables AI, AI enables personalisation, and that enables more use cases.
There is a world where medtech products differentiate not just based on hardware capabilities but also software capabilities. And in this world, the company that has the best apps, that offers the most personalisation, that covers the long tail of uses cases and maximises the device usage - wins. Europe being a launchpad for such hardware products will naturally become the launchpad for their software counterparts.
The health tech market is changing and Europe, in an unexpected turn of events, is perfectly positioned to capture the value from the start. All that is needed now is a clinical app store.